73493 Bimekizumab leads to sustained flare-free status in moderate to severe hidradenitis suppurativa: 3-year data from BE HEARD EXT
Journal of the American Academy of Dermatology · 2026-07 · 95 (1) · AB82
DOI: 10.1016/j.jaad.2026.04.337 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Academy of Dermatology, 2026-07. Verfasst von Steven Daveluy und 8 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Daveluy, S., Naik, H. B., Reguiai, Z., Yamaguchi, S., Fernandez-Peñas, P., Lukowski, B., Crater, C., Tilt, N., & Martorell, A. (2026). 73493 Bimekizumab leads to sustained flare-free status in moderate to severe hidradenitis suppurativa: 3-year data from BE HEARD EXT. Journal of the American Academy of Dermatology, 95(1), AB82. https://doi.org/10.1016/j.jaad.2026.04.337
Vancouver
Daveluy S, Naik HB, Reguiai Z, Yamaguchi S, Fernandez-Peñas P, Lukowski B, et al. 73493 Bimekizumab leads to sustained flare-free status in moderate to severe hidradenitis suppurativa: 3-year data from BE HEARD EXT. Journal of the American Academy of Dermatology. 2026;95(1):AB82. doi:10.1016/j.jaad.2026.04.337
BibTeX
@article{Daveluy2026,
author = {Daveluy, Steven and Naik, Haley B. and Reguiai, Ziad and Yamaguchi, Sayaka and Fernandez-Peñas, Pablo and Lukowski, Bartosz and Crater, Christina and Tilt, Nicola and Martorell, Antonio},
title = {73493 Bimekizumab leads to sustained flare-free status in moderate to severe hidradenitis suppurativa: 3-year data from BE HEARD EXT},
journal = {Journal of the American Academy of Dermatology},
year = {2026},
volume = {95},
number = {1},
pages = {AB82},
doi = {10.1016/j.jaad.2026.04.337}
}
EUVIMED